Navigation Links
Drug Inhibits Colon Cancer in Mice

Treated with enzastaurin, even tumors that did develop weren't as advanced, study finds

THURSDAY, Feb. 12 (HealthDay News) -- A drug called enzastaurin significantly reduced the development of colon cancer in mice, and tumors that did develop were less advanced and aggressive than those in mice that didn't receive the drug, according to a study by researchers at the Mayo Clinic in Florida.

The findings, coupled with the fact that the drug appears to have minimal side effects, suggest that enzastaurin might offer an effective chemopreventive treatment in people at high risk for colon cancer, the researchers said. The study is to be published in the Feb. 15 issue of the journal Cancer Research.

"There is a need for an agent that has a proven ability to reduce colon cancer risk, and this study suggests that enzastaurin could be uniquely effective," senior investigator Nicole Murray, of the department of cancer biology, said in a Mayo news release.

Enzastaurin is designed to suppress signaling through the PKC-beta pathway. In a previous study, the Mayo team found that the pathway is necessary for the start of colon cancer in mice exposed to a carcinogen.

"These mice develop tumors similar to tumors found in humans, but mice without the PKC-beta gene do not," Murray said.

In the new study, the Mayo researchers gave enzastaurin daily to one group of mice and then exposed them, as well as a control group of mice that didn't receive the drug, to a carcinogen that causes colon tumors.

After 22 weeks, 50 percent of the treated mice and 80 percent of the untreated mice had developed tumors. The tumors that did develop in the treated mice were not as advanced as those in the untreated mice.

Enzastaurin is currently being tested to treat a range of human cancers, including B-cell lymphoma and high-grade brain gliomas.

More information

The U.S. National Cancer Institute has more about colon cancer prevention.

-- Robert Preidt

SOURCE: Mayo Clinic, news release, Feb. 11, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
2. Herpes drug inhibits HIV replication, but with a price
3. Grapefruit Compound Inhibits Hepatitis C Virus
4. Calorie restriction inhibits, obesity fuels development of epithelial cancers
5. Calorie restriction limits Calorie restriction inhibits, obesity fuels development of epithelial can
6. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
7. Penn scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells
8. Embryonic Stem Cell Protein Inhibits Melanoma
9. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
10. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
11. Rural Areas Able to Increase Colon Cancer Screenings
Post Your Comments:
Related Image:
Drug Inhibits Colon Cancer in Mice
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: